Texinkart Inc. sold four Ayurvedic products online without FDA drug approval, FDA says.
What happened
FDA reviewed Texinkart’s website https://texinkart.com/ in April 2026 and identified four products—Thathu Busti Lehyam, Baidyanath Prostaid Tablets, Rajpro Capsules, and Rathina Purush Capsules—with labeling claims to treat disease or affect body function. FDA says the products are drugs that need FDA approval and have no approved applications, so selling them in interstate commerce violates the Federal Food, Drug, and Cosmetic Act. This was a website review, not an inspection.
What FDA found
FDA treats the four products as drugs because their website labeling claims they help with erectile dysfunction, prostate enlargement, sperm strength, semen concentration, sexual desire, or stamina.
FD&C Act § 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128FDA says the products are new drugs because they are not generally recognized as safe and effective for their labeled uses.
FD&C Act § 201(p), 21 U.S.C. 321(p)No FDA-approved applications are in effect for the products, so selling them in interstate commerce violates the unapproved new drug provisions.
FD&C Act §§ 505(a), 301(d), 21 U.S.C. 355(a), 331(d)
What FDA wants
FDA tells Texinkart to investigate and determine root causes, implement corrective and preventive measures, and send a written response with specific steps and documentation to FDAAdvisory@fda.hhs.gov within 15 business days. The response must cite reference number 729046.
Who should pay attention
- online retailers selling Ayurvedic or sexual-health products
- companies making drug claims for supplements
- regulatory teams reviewing website labeling and claims
This is a summary. Read the original letter on fda.gov.